Phase II clinical study for patients with IPF.

  • Date October 2020
  • Therapeutic Area Idiopathic Pulmonary Fibrosis
  • Study Type Phase II | Rescue
  • Challenges COVID-19 Pandemic | High patient burden (1-year-long commitment)

Responsum was brought in to boost enrollment in the US market quickly, as existing efforts had failed. The campaign has been slow in the US. 20+ randomized patients needed quickly.

Strategy and results:

Leveraging our 3.6K+ member pulmonary fibrosis community, we launched a targeted campaign centered on clinical trial education, streamlined phone screening, and a personalized email drip campaign designed to align with participants’ preferences and demographics.

52 patients were referred successfully, 13 screened, and 8 randomized. All from our IPF community.

Testimonials and reviews from our customers

What our customers are saying about us